How do you manage hematologic toxicities in solid tumor patients treated with immune checkpoint inhibitors?   

While hematological side effects of checkpoint inhibitor therapy are uncommon, they do occur and certainly can run the gamut of any and all autoimmune manifestations of hematological disease. In my own experience I have seen patients with ITP on anti-PD1/PD-L1 therapy and others such as autoimmune h...